 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Xenogen Corporation
 |
Xenogen Corporation |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
IPO Weekly: Can KPMG Consulting Loosen the IPO Log Jam?
Feb 02 2001 04:33 PM PST
IPO Weekly: The Window Opens - Slightly
Jan 26 2001 04:49 PM PST
PROFILE |
 |
Xenogen wants to light up the biotech world. The biotechnology firm develops, manufactures, and markets "in vivo" biophotonic imaging systems designed to allow speedier drug discovery and development. Xenogen's "in vivo" biophotonic system adds luciferase, which produces a light-emitting enzyme, into tumor cells. Highly sensitive cameras capture the emitted light and its LivingImage software helps record and analyze the data. The company has licensed its real-time "in vivo" imaging technology to such firms as SUGEN, Onyx Pharmaceuticals, Chiron, AstraZeneca, and GlaxoSmithKline.
COMPETITION |
 |
Aurora Biosciences Corporation (dossier)
Deltagen, Inc. (DGEN)
Lexicon Genetics Incorporated (LEXG)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 1.30
1-Yr. Sales Growth: 1,439.3%
Employees: 72
Revenue per employee: $18,055.56
KEY PEOPLE |
 |
Pamela R. Contag
CEO
Kevin J. Birtchnell
CFO
CONTACT INFO |
 |
860 Atlantic Ave.
Alameda, CA 94501
US
Phone: 510-291-6100
Fax: 510-291-6196
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |